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Only one step from tailored oncological therapies
Paweł Krawczyk
The personalization of oncological therapy is becoming a reality thanks to the development of molecular biology 
techniques (e.g. next generation sequencing, liquid biopsy) and the discovery of new molecularly targeted therapies 
and immunotherapeutics. Genetic laboratories and clinical centers, which form international networks as well as global, 
early phase clinical trials make it possible to match treatments to a particular patient. The benefit of such a procedure 
is currently difficult to estimate, but it seems that another path for the development of oncology is not possible.
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Introduction 
Tailored oncological treatment based on molecularly 
targeted therapies and immunotherapies play increasing 
role in the multidisciplinary approach to cancer patient care. 
Treatment personalization extends the scope of therapy and 
extends the survival of patients. An example of lung cancer 
treatment personalization is our 57-year-old male patient 
with advanced lung adenocarcinoma and activating EGFR 
gene mutations, as well as PD-L1 expression. As the methods 
of treatment, we used segmentectomy (diagnostic manner), 
hemipelvectomy of metastases in the right hip joint with 
postsurgical radiotherapy, surgical cytoreduction, and six 
lines of systemic treatment which were based on standard 
cytostatics and novel personalized agents. The presence of 
the coexistence of rare mutations in exon 18 of the EGFR 
gene (G719X and G709X) in tumor cells allowed the use of 
the first-generation (erlotinib) of tyrosine kinase inhibitor 
(TKI) of EGFR (epidermal growth factor receptor). The appe-
arance of the Thr790Met mutation in exon 20 of the EGFR 
gene, in circulating tumor DNA (ct-DNA) from peripheral 
blood, during the progression to erlotinib allowed the use of 
the third generation of EGFR-TKI (osimertinib). The presence 
of PD-L1 expression on tumor cells justified the attempt 
to apply immunotherapy (nivolumab — anti-PD-1 antibo-
dy). The patient also received a tyrosine kinase inhibitor of 
VEGFR, FGFR and PDGFR (nintedanib) in combination with 
chemotherapy. As a result, we have achieved long-term 
overall survival with long progression-free periods during 
individual therapy [1].
Of course, such a therapeutic approach could be regar-
ded as unattainable for larger groups of patients. Personali-
zed therapies are available only in developed countries with 
access to modern genetic methods of cancer diagnosis and 
to clinical trials with novel drugs. Today, personalized the-
rapies could be used in a small percentage of patients with 
a genetic predisposition to the treatment. Moreover, cancer 
cells can develop resistance to even the best molecularly 
targeted therapies and immunotherapies. Tumors are also 
molecularly heterogeneous, so it is difficult to find for our 
patients appropriate and permanently effective personali-
zed therapy. However, the development of new molecular 
methods (especially next generation sequencing and liquid 
biopsy) and the discovery of new drugs investigated in cli-
nical trials raise the hope that precise oncology has arrived.
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Next generation sequencing and liquid biopsy in 
qualification to personalized treatment in cancer 
patients
Next generation sequencing (NGS) is a new DNA 
sequencing technology which has revolutionized genomic 
research. Using NGS, the whole genome of cancer cells 
(whole genome sequencing, WGS) can be sequenced within 
a single day, and the price of the examination has dropped 
so much that WGS could be available to even individual 
patients. In contrast, the previous Sanger direct technology 
required over a decade in order to map the human genome. 
NGS is increasingly translated into routine clinical practi-
ce, especially in oncology and in pediatrics. NGS could be 
used to sequence whole genome or specific genome areas, 
including coding sequences (whole exome sequencing, 
WES) and individual genes (e.g. oncogenes with “druggable” 
mutations). There are a number of different NGS platforms 
using different sequencing technologies. In a very simplistic 
way, all NGS technologies use three stages [2, 3]: 
1. Library preparation with DNA fragmentation and in vitro 
adaptor ligation.
2. Clonal amplification using an emulsion or bridge PCR 
(polymerase chain reaction).
3. Cyclic sequencing of millions of small fragments of DNA 
in parallel using pyrosequencing, sequencing by ligation 
or sequencing by synthesis.
WES or sequencing of selected genes are most com-
monly used in the personalization of oncological treatment. 
The sequencing of frequently mutated genes in tumor cells in 
particular malignancies, is the most meaningful, cost-effective 
and rapid method to qualify to molecularly targeted drugs. 
These mutations should cause changes in proteins involved in 
intracellular pathways which could be blocked by molecularly 
targeted drugs. WES may be a useful method to evaluate the 
number of mutations in tumors (tumor mutation burden) in 
qualification to immunotherapy (a large number of mutations 
results in the increased number of tumor-specific antigens 
and increased efficacy of immunotherapy) [2, 3].
Several diagnostic companies propose the sequencing 
of selected genes to qualify individual patients for molecu-
larly targeted therapies (e.g. FoundationOne, OncoDNA, 
ONCOMPASS, Caris, Guardant 360). NGS is not only offered 
to detect gene mutations (indels, substitutions, single nuclo-
etide transcriptional variants (SNVs), but also for gene copy 
number variations (CNV) and chromosome translocation 
(rearrangement) analysis or epigenetic analysis (promoter 
genes methylation). In offers, NGS analysis is supplemented 
by simpler genetic methods, e.g. immunohistochemistry 
(IHC) for assessment of protein expression, fluorescence 
in situ hybridization (FISH) for chromosomal abnormality 
analysis, and real-time PCR technique for single mutation 
analysis. The patients’ report should consist not only of the 
result of genetic tests, but also of the the analysis of the 
availability of personalized treatment (chemotherapy, mo-
lecularly targeted therapies, immunotherapy). Such a report 
takes into account therapies registered for treatment of 
particular cancers, therapies registered for other indica-
tions (potentially useable due to the occurrence of genetic 
alterations), and drugs in clinical trials (often available in 
distant locations) [2, 3].
The possibility of genetic diagnostics and qualification 
for molecularly targeted therapies and immunotherapy has 
considerably expanded through the introduction of analysis 
of genetic materials from peripheral blood (liquid biopsy), 
with highly sensitive molecular methods (e.g. some NGS 
techniques, droplet digital PCR and BEAMing PCR). Circula-
ting tumor DNA (ctDNA) is now being extensively studied, 
as it is a noninvasive “real-time” biomarker that can provide 
diagnostic and prognostic information before, during tre-
atment and at progression. These include DNA mutations, 
epigenetic alterations and other forms of tumor-specific 
abnormalities such as microsatellite instability (MSI) and 
loss of heterozygosity (LOH). The major challenge of genetic 
analysis of material from liquid biopsy is assay sensitivity. 
Frequent EGFR gene mutations (deletions in exon 19 and 
Leu858Arg substitution in exon 21) are detected in liquid 
biopsies of non-small cell lung cancer (NSCLC) patients with 
a sensitivity of 60–75%. Therefore, the tumor tissue or cells 
are the most important material for examination of these 
mutations during qualification of NSCLC patients to EGFR-
-TKI therapy. However, the use of liquid biopsy for detection 
of EGFR mutations, responsible for EGFR-TKI resistance du-
ring disease progression (e.g. Thr790Met substitution in 
exon 20), extends the ability of patient qualification to third 
generation EGFR-TKI (osimertinib). Moreover, analysis of 
genetic materials from liquid biopsy allows determination 
of the moment of molecular progression (the appearance of 
genetic material of cancer cells in peripheral blood). In ad-
dition, examination of genetic mutations in ctDNA allows 
the selection of appropriate molecularly targeted compo-
unds. A good example is the treatment of NSCLC patients 
with ALK gene rearrangement using various ALK inhibitors 
(crizotinib, ceritinib, alectinib, lorlatinib). Recently identified 
ALK gene mutations are responsible for differences in the 
sensitivity of ALK inhibitors. Therefore, identification of the 
appearance of ALK mutations during ALK inhibitor treatment 
allows qualification to appropriate next generation drugs 
and selection of the appropriate treatment sequence for 
these drugs [4–6].
The concept of an oncology center network with 
access to molecular diagnosis and clinical trials 
with new molecularly targeted therapies
The National Comprehensive Cancer Network develo-
ped clinical practice guidelines in oncology for non-small-
-cell lung cancer diagnosis and treatment. These guidelines 
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include recommendations to perform tests for EGFR mu-
tation and ALK rearrangement detection, and also exami-
nation of BRAF V600E mutation, MET amplification, MET 
exon 14 skipping mutation, RET rearrangements and HER2 
mutations. Targeted agents studied in advanced clinical 
trials are available for patients with these genetic abnor-
malities. Genetic abnormalities in more than 10 genes in 
tumor cells have become “druggable” in lung cancer patients 
[6]. The Lung Cancer Mutation Consortium published data 
about the effectiveness of molecularly targeted therapies in 
molecularly predisposed lung cancer patients. The median 
overall survival (OS) of patients with different “druggable” 
mutations, who received matched molecularly targeted 
therapies, was significantly longer than the median OS of 
patients without genetic abnormalities or patients with 
genetic alterations who could not be treated with molecu-
larly targeted therapies. The organization of such a clinical 
trial and the availability of a variety of molecularly targeted 
therapies and genetic tests, were possible thanks to the 
participation of many American clinical centers. Similar 
multi-center diagnostic and clinical networks operate in 
EU countries (e.g. Cancer Research UK). Such cooperation 
enabled the organization of several clinical trials in which 
treatment was personalized based on the molecular profile 
of cancer cells, in patients with different types of neoplasms 
[7].
The IMPACT 1 study enrolled 3536 patients with 15 dif-
ferent advanced malignancies. In 2089 patients (59%), at 
least one “druggable” genetic abnormality was detected, 
and more than 3 such abnormalities were diagnosed in 
359 (10.2%). Patients with melanoma, as well as with breast, 
endometrium, colorectal and ovarian cancer, presented 
genetic abnormalities in tumor cells most often. Response 
to treatment and disease control were reported in 21% and 
42% of the patients treated with a therapy based on the 
molecular profile of cancer cells. In comparison, in patients 
without feasibility of tailored therapy, the response rate to 
chemotherapy was 6%, and disease control was observed 
in 19% of cases. The use of tailored therapy enabled prolon-
gation of progression free survival from 2.4 to 4.1 months 
and overall survival from 8.2 to 10.2 months. Based on these 
findings, the IMPACT 2 study was started in patients with 
advanced solid tumors [8].
It is worth mentioning that other clinical trials have 
been conducted on a similar basis, and their results are 
expected in the coming months. The multicenter SWOG 
S1400 phase II clinical trial enrolled patients with advan-
ced squamous cell lung cancer. PIK3CA mutations, CCND1 
amplification, CDKN2 deletion, RB mutations, FGFR mu-
tations, rearrangement and amplification, as well as MET 
expression, were examined in all SCC patients. Based on 
the detected genetic abnormalities, patients could be 
treated with inhibitors of PIK3CA, CDK 4 or 6, FGFR and 
HGF in combination with chemotherapy or erlotinib [9]. 
The BATTLE-2 study was dedicated to advanced NSCLC 
patients. Genetic abnormalities detected in cancer cells 
determined the use of inhibitors of EGFR (erlotinib), RAF 
(sorafenib), MEK (selumetinib) or AKT (MK 2206) [10].
Selection of individualized treatments based on genetic 
analysis of paired tumor and normal tissue was performed 
in the global WINTHER study. In 200 patients biopsies of me-
tastatic lesions and matched normal tissue were executed 
in order to obtain material for whole genome sequencing. 
Patients with molecular predictive factors received matched 
molecular targeted therapies including drugs in the opened 
1st phase clinical trials. In patients without such predictive 
factors, oncologists used therapeutic choice based on pre-
dictive drug efficacy scoring [11].
The SHIVA clinical trials enrolled patients with recur-
rent and refractory to standard treatment solid tumors. 
Molecular profiling using the NGS technique is performed 
in tumor biopsy. After centralized bioinformatics analysis 
of the genetic results, the molecular biology board makes 
the treatment decision. Eligible patients are randomized 
to molecularly targeted therapies or to treatment at the 
physician’s choice. Treatment cross over is possible at the 
time of disease progression [12, 13].
The National Cancer Institute — MATCH Clinical Trial 
explores the possibilities of the introduction to routine 
practice of novel treatment methods based on molecular 
profiles of patients’ tumors. About 6000 patients with solid 
tumors (including rare tumors, lymphomas and myeloma) 
that no longer respond to standard treatment are screened 
with a tumor biopsy. Changes in 143 genes are diagnosed 
using the NGS technique. If a patient’s tumors have genetic 
abnormalities that match the one targeted by a drug used 
in clinical trial, the patient are eligible to join the treatment 
portion of NCI-MATCH. 30 different therapies that target 
30 different genetic abnormalities are available for cancer 
patients taking part in this clinical trial [3, 14].
Conclusion
Tremendous progress in molecular biology and the 
development of new molecularly targeted drugs allow tre-
atment personalization for very narrow, genetically selected 
groups of cancer patients. The nature of clinical trials is 
evolving. In the previous decade, large clinical trials of the 
3rd phase have been dominant, enrolling hundreds and 
even thousands of patients. Currently, early phase clinical 
trials enroll only individual patients with a genetic predi-
sposition to an individual treatment method. Therefore, the 
effectiveness of the investigated drugs is discussed on the 
basis of individual case reports. Patients actively search for 
such clinical trials, traveling around the world for treatment. 
Often, such an attitude prolongs their life just enough to 
make even one of their dreams come true. 
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